<DOC>
	<DOCNO>NCT00114777</DOCNO>
	<brief_summary>The purpose trial learn Belatacept effective safe first line immunosuppression treatment patient undergo renal transplant donor kidney obtain patient extend criterion .</brief_summary>
	<brief_title>Study Belatacept Subjects Who Are Undergoing Renal Transplant</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>Subject firsttime recipient kidney transplant decease donor . Specific donor criterion Donor age &lt; 10 year Subjects receive concurrent solid organ cell transplant ( lung , heart , etc . ) Subjects positive Tcell lymphocytotoxic crossmatch . Subjects positive Hepatitis B C , HIV Active TB History cancer last 5 year History substance abuse Specific laboratory result exclusionary Mammography suspicious cancer Allergy iodine For Longterm extension studySubjects complete three year study treatment ( Week 156 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>